Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141187 | 1.00 | HTR3A (0.46) | HTR3AHTR2AHTR2CHTR2BGRIA4 | |
| SCHEMBL2141184 | 1.00 | HTR3A (0.46) | HTR3AHTR2AHTR2CHTR2BGRIA4 | |
| Hydrochloric Acid SCHEMBL7309317 | 0.98 | HTR2A (0.47) | HTR3AHTR2AHTR2CHTR2BGRIA4 | |
| SCHEMBL1644778 | 0.96 | HTR3A (0.46) | HTR3AHTR2AHTR2CHTR2BGRIA4 | |
| SCHEMBL4258361 | 0.96 | HTR3A (0.46) | HTR3AHTR2AHTR2CHTR2BGRIA4 | |
| SCHEMBL4258364 | 0.96 | HTR3A (0.46) | HTR3AHTR2AHTR2CHTR2BGRIA4 | |
| SCHEMBL17806041 | 0.87 | HTR2A (0.47) | HTR3AHTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL16451639 | 0.87 | HTR2A (0.47) | HTR3AHTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL15291807 | 0.87 | HTR2A (0.47) | HTR3AHTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL15282173 | 0.87 | HTR2A (0.47) | HTR3AHTR2AHTR2CHTR2BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4666533-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | claimed |
| JP-2008524279-A | — | — | 2008-07-10 | — | — | JP | claimed |
| EP-1833782-A1 | CYCLOALKYLAMINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | claimed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | claimed |
| EP-2326633-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8722688-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-13 | — | — | US | disclosed |
| US-8309558-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | disclosed |
| US-4153235-A | HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC ACTIVITIES | RICHARDSON-MERRELL INC. (US) | 1979-05-08 | — | — | US | disclosed |
| US-4126613-A | HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC | RICHARDSON-MERRELL INC. (US) | 1978-11-21 | — | — | US | disclosed |
| US-4126611-A | HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC | RICHARDSON-MERRELL INC. (US) | 1978-11-21 | — | — | US | disclosed |
| US-4126621-A | HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC | RICHARDSON-MERRELL INC. (US) | 1978-11-21 | — | — | US | disclosed |
| US-4126612-A | HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC | Retter, Eugene O. (US) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | DPP4, DPP7, DPP3 | HTR3A 1368/4885HTR2A 1865/4885HTR2C 1770/4885 |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HTR3A 4027/4885HTR2A 4609/4885HTR2C 3275/4885 |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HTR3A 4027/4885HTR2A 4609/4885HTR2C 3275/4885 |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | HTR3A 4027/4885HTR2A 4609/4885HTR2C 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.